Treatment of gastric cancer
Treatment of gastric cancer
复制标题
DOI：
10.3748/wjg.v20.i7.1635
复制
发表时间：
2014-02-21
影响因子：
4.3
通讯作者：
De Vita, Ferdinando
中科院分区：
文献类型：
--
作者：
Orditura, Michele;Galizia, Gennaro;De Vita, Ferdinando
作者关注了可切除胃癌的当前手术治疗以及围手术期和术后化疗或放化疗的意义。胃癌是全球第四大常见确诊癌症以及癌症死亡的第二大主要原因。手术仍然是唯一的治愈性疗法，而围手术期和辅助化疗以及放化疗可改善进行了扩大淋巴结清扫的可切除胃癌的预后。超过一半的根治性切除胃癌患者局部复发或出现远处转移，或者在肿瘤播散时才被诊断出胃癌；因此，中位生存期很少超过12个月，5年生存率低于10%。以顺铂和氟嘧啶为基础的化疗，在人表皮生长因子受体2阳性患者中加入曲妥珠单抗，是适合化疗的Ⅱ期患者广泛使用的治疗方法。近期证据支持身体状况良好的患者病情进展后使用二线化疗。(C)2014百世登出版集团有限公司。保留所有权利。
The authors focused on the current surgical treatment of resectable gastric cancer, and significance of peri-and post-operative chemo or chemoradiation. Gastric cancer is the 4th most commonly diagnosed cancer and the second leading cause of cancer death worldwide. Surgery remains the only curative therapy, while perioperative and adjuvant chemotherapy, as well as chemoradiation, can improve outcome of resectable gastric cancer with extended lymph node dissection. More than half of radically resected gastric cancer patients relapse locally or with distant metastases, or receive the diagnosis of gastric cancer when tumor is disseminated; therefore, median survival rarely exceeds 12 mo, and 5-years survival is less than 10%. Cisplatin and fluoropyrimidine-based chemotherapy, with addition of trastuzumab in human epidermal growth factor receptor 2 positive patients, is the widely used treatment in stage. patients fit for chemotherapy. Recent evidence supports the use of second-line chemotherapy after progression in patients with good performance status (C) 2014 Baishideng Publishing Group Co., Limited. All rights reserved.